Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no
effective and safe medications approved for the treatment of abdominal pain associated with
bowel symptoms in IBS. This study will investigate the effects of an approved medication,
Dronabinol, on the movement of food through the stomach and colon in subjects with a history
of diarrhea-predominant Irritable Bowel Syndrome (D-IBS).
Phase:
Phase 2
Details
Lead Sponsor:
Michael Camilleri
Collaborators:
National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)